Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy

Abstract To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 re...

Full description

Bibliographic Details
Main Authors: Julian A. Luetkens, Anne C. Wolpers, Thomas Beiert, Daniel Kuetting, Darius Dabir, Rami Homsi, Hendrik Meendermann, Natalie Abou Dayé, Vincent Knappe, Morten Karsdal, Signe H. Nielsen, Federica Genovese, Florian Stöckigt, Markus Linhart, Daniel Thomas, Georg Nickenig, Hans H. Schild, Jan W. Schrickel, René P. Andrié
Format: Article
Language:English
Published: Nature Publishing Group 2018-09-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-018-31916-2
id doaj-a791bc9426054598af890b1907253b3b
record_format Article
spelling doaj-a791bc9426054598af890b1907253b3b2020-12-08T05:02:35ZengNature Publishing GroupScientific Reports2045-23222018-09-01811910.1038/s41598-018-31916-2Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapyJulian A. Luetkens0Anne C. Wolpers1Thomas Beiert2Daniel Kuetting3Darius Dabir4Rami Homsi5Hendrik Meendermann6Natalie Abou Dayé7Vincent Knappe8Morten Karsdal9Signe H. Nielsen10Federica Genovese11Florian Stöckigt12Markus Linhart13Daniel Thomas14Georg Nickenig15Hans H. Schild16Jan W. Schrickel17René P. Andrié18Department of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityFibrosis Biology and Biomarkers, Nordic BioscienceFibrosis Biology and Biomarkers, Nordic BioscienceFibrosis Biology and Biomarkers, Nordic BioscienceDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityAbstract To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation times were assessed using CMR. Plasma levels of relaxin, myeloperoxidase and serum levels of matrix metalloproteinase (MMP)-mediated cardiac specific titin fragmentation and MMP-mediated type IV collagen degradation were obtained. Poor outcome was defined by the recurrence of AF during 1-year follow-up. 61 patients were included in final analysis. Twenty (32.8%) patients had recurrence of AF. Patients with a recurrence of AF had a higher percentage of LA LGE (26.7 ± 12.5% vs. 17.0 ± 7.7%; P < 0.001), higher LA T1 relaxation times (856.7 ± 112.2 ms vs. 746.8 ± 91.0 ms; P < 0.001) and higher plasma levels of relaxin (0.69 ± 1.34 pg/ml vs. 0.37 ± 0.88 pg/ml; P = 0.035). In the multivariate Cox regression analysis, poor ablation outcome was best predicted by advanced LGE stage (hazard ratio (HR):5.487; P = 0.001) and T1 relaxation times (HR:1.007; P = 0.001). Pre-procedural CMR is a valuable tool for prediction of poor response to catheter ablation therapy in patients with AF. It offers various imaging techniques for outcome prediction and might be valuable for a better patient selection prior to ablation therapy.https://doi.org/10.1038/s41598-018-31916-2Catheter Ablation TherapyLate Gadolinium Enhancement (LGE)RelaxinFibrotic BiomarkersLeft Atrial (LA)
collection DOAJ
language English
format Article
sources DOAJ
author Julian A. Luetkens
Anne C. Wolpers
Thomas Beiert
Daniel Kuetting
Darius Dabir
Rami Homsi
Hendrik Meendermann
Natalie Abou Dayé
Vincent Knappe
Morten Karsdal
Signe H. Nielsen
Federica Genovese
Florian Stöckigt
Markus Linhart
Daniel Thomas
Georg Nickenig
Hans H. Schild
Jan W. Schrickel
René P. Andrié
spellingShingle Julian A. Luetkens
Anne C. Wolpers
Thomas Beiert
Daniel Kuetting
Darius Dabir
Rami Homsi
Hendrik Meendermann
Natalie Abou Dayé
Vincent Knappe
Morten Karsdal
Signe H. Nielsen
Federica Genovese
Florian Stöckigt
Markus Linhart
Daniel Thomas
Georg Nickenig
Hans H. Schild
Jan W. Schrickel
René P. Andrié
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
Scientific Reports
Catheter Ablation Therapy
Late Gadolinium Enhancement (LGE)
Relaxin
Fibrotic Biomarkers
Left Atrial (LA)
author_facet Julian A. Luetkens
Anne C. Wolpers
Thomas Beiert
Daniel Kuetting
Darius Dabir
Rami Homsi
Hendrik Meendermann
Natalie Abou Dayé
Vincent Knappe
Morten Karsdal
Signe H. Nielsen
Federica Genovese
Florian Stöckigt
Markus Linhart
Daniel Thomas
Georg Nickenig
Hans H. Schild
Jan W. Schrickel
René P. Andrié
author_sort Julian A. Luetkens
title Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_short Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_full Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_fullStr Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_full_unstemmed Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_sort cardiac magnetic resonance using late gadolinium enhancement and atrial t1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
publisher Nature Publishing Group
series Scientific Reports
issn 2045-2322
publishDate 2018-09-01
description Abstract To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation times were assessed using CMR. Plasma levels of relaxin, myeloperoxidase and serum levels of matrix metalloproteinase (MMP)-mediated cardiac specific titin fragmentation and MMP-mediated type IV collagen degradation were obtained. Poor outcome was defined by the recurrence of AF during 1-year follow-up. 61 patients were included in final analysis. Twenty (32.8%) patients had recurrence of AF. Patients with a recurrence of AF had a higher percentage of LA LGE (26.7 ± 12.5% vs. 17.0 ± 7.7%; P < 0.001), higher LA T1 relaxation times (856.7 ± 112.2 ms vs. 746.8 ± 91.0 ms; P < 0.001) and higher plasma levels of relaxin (0.69 ± 1.34 pg/ml vs. 0.37 ± 0.88 pg/ml; P = 0.035). In the multivariate Cox regression analysis, poor ablation outcome was best predicted by advanced LGE stage (hazard ratio (HR):5.487; P = 0.001) and T1 relaxation times (HR:1.007; P = 0.001). Pre-procedural CMR is a valuable tool for prediction of poor response to catheter ablation therapy in patients with AF. It offers various imaging techniques for outcome prediction and might be valuable for a better patient selection prior to ablation therapy.
topic Catheter Ablation Therapy
Late Gadolinium Enhancement (LGE)
Relaxin
Fibrotic Biomarkers
Left Atrial (LA)
url https://doi.org/10.1038/s41598-018-31916-2
work_keys_str_mv AT julianaluetkens cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT annecwolpers cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT thomasbeiert cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT danielkuetting cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT dariusdabir cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT ramihomsi cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT hendrikmeendermann cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT natalieaboudaye cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT vincentknappe cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT mortenkarsdal cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT signehnielsen cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT federicagenovese cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT florianstockigt cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT markuslinhart cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT danielthomas cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT georgnickenig cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT hanshschild cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT janwschrickel cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT renepandrie cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
_version_ 1724391911951695872